Table 1.

Agonistic CD40 monoclonal antibodies in clinical trials^*

	mAb
	CP-870,893	Dacetuzmumab	Chi Lob 7/4
Company/Institution	Pfizer/VLST	Seattle Genetics	Univ. of Southampton
Formulation	Fully human	Humanized	Chimeric
Isotype	IgG2	IgG1	IgG1
Maximum dose	0.2 mg/kg	Up to 12 mg/kg	Up to 160 mg total
Route of administration	i.v	i.v.	i.v.
Dosing interval	Every 3–4 weeks	Weekly	Weekly × 4
Toxicity	Mild to moderate cytokine release syndrome	Mild to moderate cytokine release syndrome Non-infectious inflammatory eye disorders	Study to address is underway
Diseases targeted	Melanoma Pancreatic carcinoma Mesothelioma	Hematological malignancies, especially Non-Hodgkin's lymphoma	Advanced solid tumors and lymphoma
Clinical efficacy	Objective tumor responses reported in melanoma and pancreatic carcinoma (about 20%)	Objective tumor responses (in refractory and relapsed NHL, 12% as single agent; 47% with rituximab and gemcitabine)	Study to address is underway
Combinations explored	Chemotherapy Melanoma vaccine Tremelimumab	Chemotherapy Rituximab	None yet
Current clinical trials	With tremelimumab in metastatic melanoma With gemcitabine for resectable pancreatic carcinoma	None	First-in-human trial for patients with advanced solid tumors and lymphoma

^*only reagents showing agonistic activity are included and thus lucatumumab (Novartis) has not been discussed